# A Phase III Confirmatory Study of K-877 Extended Release Tablet

Study · id `cardio:ct-nct04714151` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04714151](<https://clinicaltrials.gov/study/NCT04714151>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04714151

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 356 participants.

## Technical summary

Registry record NCT04714151. Randomized; quadruple masking; primary purpose treatment. Start 2021-02-01 (actual); primary completion 2021-09-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 356 participants (enrolled count; ClinicalTrials.gov record NCT04714151, source copy `cardio:ctgov-nct04714151-2024-06-20`, retrieved 2026-10-31)
- Started: 2021-02-01 (actual) (ClinicalTrials.gov record NCT04714151, source copy `cardio:ctgov-nct04714151-2024-06-20`, retrieved 2026-10-31)
- Primary completion: 2021-09-25 (actual) (ClinicalTrials.gov record NCT04714151, source copy `cardio:ctgov-nct04714151-2024-06-20`, retrieved 2026-10-31)
- Completion: 2021-09-25 (actual) (ClinicalTrials.gov record NCT04714151, source copy `cardio:ctgov-nct04714151-2024-06-20`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT04714151, source copy `cardio:ctgov-nct04714151-2024-06-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04714151-2024-06-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase III Confirmatory Study of K-877 Extended Release Tablet
- Condition: Dyslipidemias
- Intervention (Drug): K-877 ER 0.2 mg/day (once daily)
- Intervention (Drug): K-877 ER 0.4 mg/day (once daily)
- Intervention (Drug): K-877 IR 0.2 mg/day (twice daily)
- Lead sponsor: Kowa Company, Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Kowa Company, Ltd. (`cardio:org-kowa-company-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial (`cardio:pubmed-38616112`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: bcacf4b14f175935e904bc068c2c4010ebe49341ebf6c789ec14d7ea701badcb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
